论文部分内容阅读
目的:研究重组人血管内皮抑制素联合TP方案治疗晚期非小细胞肺癌(NSCLC)的临床效果。方法:选取2012年8月至2015年7月该院收治的晚期NSCLC的患者68例,根据治疗方法的不同将患者分为TP组和联合组,每组34例。TP组单纯采用TP方案化疗,联合组给予重组人血管内皮抑制素联合TP方案治疗。观察两组患者的治疗效果。结果:观察组患者的治疗有效率为61.77%,显著高于对照组的(32.35%,P<0.05);观察组患者的疾病控制率为94.12%,显著高于对照组的(76.47%,P<0.05)。结论:重组人血管内皮抑制素联合TP方案治疗晚期NSCLC具有协同作用,提高了治疗的有效率和疾病控制率,效果显著,值得推广应用。
Objective: To study the clinical effect of recombinant human endostatin combined with TP regimen in the treatment of advanced non-small cell lung cancer (NSCLC). Methods: Sixty-eight patients with advanced NSCLC admitted to our hospital from August 2012 to July 2015 were selected. Patients were divided into TP group and combination group according to the different treatment methods, with 34 cases in each group. TP group chemotherapy alone TP regimen, the combined group given recombinant human endostatin TP regimen. Observed the treatment effect of two groups of patients. Results: The treatment effective rate in the observation group was 61.77%, which was significantly higher than that in the control group (32.35%, P <0.05). The disease control rate in the observation group was 94.12%, significantly higher than that in the control group (76.47%, P <0.05). Conclusion: Recombinant human endostatin combined with TP regimen in the treatment of advanced non-small cell lung cancer has synergistic effect, which improves the efficiency of treatment and the rate of disease control. It has great effect and is worth popularizing and applying.